Asthma

Oral Dexpramipexole.
Our Novel Candidate for Eosinophilic Asthma

50%

of all patients suffering with severe asthma have elevated numbers of eosinophils in their blood and lungs.

High levels of eosinophils increase the risk of asthma attacks and lung damage.

At present, the only treatments for eosinophilic asthma come in the form of injections or infusions.

Dexpramipexole is an experimental drug shown to block eosinophils from maturing in the bone marrow, and is under investigation as a potential treatment for eosinophilic asthma.

Ongoing clinical research on the role of eosinophils in asthma has already created benefits for many patients.